ESMO 2019 Updated IMpower110 Trial Results: With Consistent OS/PFS Improvement, Atezolizumab Is a New 1st-Line Treatment Option for PD-L1-High Stage IV NSCLC

1,741 views
January 7, 2020
Comments 2
Login to view comments. Click here to Login